I am cautiously optimistic. I admit I was very excited when I came across this press release that was posted to The Lung Transplant Foundation‘s Facebook page. As usual, I try to temper my excitement with the reality we won’t know what’s possible for awhile or if this is just a step in the right direction.
I realize the drug is only in Phase II trials now, but it does show promise. Continue reading
On December 10, 2015 the American Thoracic Society (ATS) & the Lung Transplant Foundation (LTF) jointly hosted a webinar for Lung Transplant Week at the ATS. The clinician presenter was Cynthia Gries, Director of Lung Transplantation at the Florida Hospital Transplant Institute. Continue reading
I’ve spoken to the American Thoracic Society (ATS) before, worked with them professionally through Medscape, & on some other nonprofit projects. I love this organization for several reasons. One of them being that they circulate so much good information on so many different diseases.
The Lung Transplant Foundation (LTF) Foundation also puts great & accurate information out on their social media outlets. That’s how I came to find out about them.
I’m glad both organizations put together this joint effort for this week to raise awareness about lung transplants.
I was hesitant to share this particular news before because I couldn’t find any real sources to verify what phase of clinical trial it was in. But I find this news highly promising. Yet, I’m trying not to get my hopes up too soon.
This is an issue I continue to struggle with even having discourse about. How much of my reality/health status do I discuss with my employer & or colleagues? Do I disclose anything & when? If I’m looking for a job when do I bring the subject up? I came across this article. That’s what triggered these thoughts; even now, when I’m not working, because I remember those days all too well. They weren’t that long ago.
This article’s interpretation of the study may be really technical for the everyday person to understand completely, but I feel it’s worthy of a mention regardless. Also, it’s not proven fact yet because it’s only preclinical data. That said, it’s promising. Certainly worth further study, especially if it leads to better & earlier detection of rejection & infection. The added bonus is that it is a noninvasive & less expensive means of testing, which I know any transplantee (pre or post) would certainly welcome.
In my blog post from 8/4/15, I talked about a transplant innovation called ex-vivo lung perfusion (EVLP). If you missed that post, you may want to go back & read it before reading this one. (I just linked to it if you need bounce back).